The Latest Cardiac and Vascular News
Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrillation Late-breaking findings presented at ACC.26 and simultaneously published in The New…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm.
Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category.
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of pre-clinical results of the Company’s next generation ultra-low temperature ablation (“ULTA”) technology designed to treat ventricular arrhythmias. The publication, which is titled “Initial Pre‐Clinical Evaluation of the Augmented Ultra‐Low Temperature Cr
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful completion of 13 ventricular ablation procedures at leading institutions using the Company’s proprietary Ultra-Low Temperature Ablation (ULTA) technology under Expanded Access authorization from the U.S. Food and Drug Administration (FDA). The procedures addr
LIMA, Peru–(BUSINESS WIRE)–Johnson & Johnson announced the arrival in Peru of a new pulsed field ablation (PFA) technology for the treatment of drug-refractory paroxysmal atrial fibrillation. This incorporation represents a significant advance in the approach to cardiac arrhythmias, with benefits in terms of safety, precision, and procedural efficiency.1 “With this launch, Peru joins the Latin American countries that already have this world-class innovation, used in international referenc
NEW YORK–(BUSINESS WIRE)–ACCESS GPO today announced a preferred, multi-year agreement with Medtronic to support availability of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter in ambulatory surgery centers (ASCs) across the United States. The agreement is designed to help physician-led ASCs gain earlier access to next-generation technology for treatment of cardiac arrhythmias in the ASC setting. Pulsed field ablation (PFA) is emerging as one of the most important advances in t
HeartBeam’s technology uniquely capable of assessing possible heart attacks outside of traditional clinical settings ALIGN-ACS study expected to complete patient enrollment quickly Milestone signifies key step toward future FDA indication expansion for heart attack assessment Future indication expansion would unlock large market with over 20 million patients at risk of a […]
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market
LOS ALTOS, Calif., March 4, 2026 /PRNewswire/ — XYRA LLC announces that the US Patent and Trademark Office (USPTO) has issued a patent (No. 12,551,706) protecting the use of dose adjusted budiodarone for the treatment of atrial fibrillation (AF), with monitoring to correspondingly reduce…
